- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy ; volume:4 ; number:1 ; day:16 ; month:8 ; year:2016 ; pages:1-11 ; date:12.2016
Journal for ImmunoTherapy of Cancer ; 4, Heft 1 (16.8.2016), 1-11, 12.2016
- Urheber
-
Heinzerling, Lucie
- Beteiligte Personen und Organisationen
-
Ott, Patrick A.
Hodi, F. Stephen
Husain, Aliya N.
Tajmir-Riahi, Azadeh
Tawbi, Hussein
Pauschinger, Matthias
Gajewski, Thomas F.
Lipson, Evan J.
Luke, Jason J.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-016-0152-y
- URN
-
urn:nbn:de:1111-201609011020
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heinzerling, Lucie
- Ott, Patrick A.
- Hodi, F. Stephen
- Husain, Aliya N.
- Tajmir-Riahi, Azadeh
- Tawbi, Hussein
- Pauschinger, Matthias
- Gajewski, Thomas F.
- Lipson, Evan J.
- Luke, Jason J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy